Systemic AL (λ) Amyloidosis Discovered After Neoadjuvant Pembrolizumab‐Based Chemoimmunotherapy for Resectable NSCLC: Case Report

ABSTRACT Systemic AL amyloidosis is rarely reported in temporal association with immune checkpoint inhibitor use. We report a 69‐year‐old man with resectable stage IIB right upper lobe lung adenocarcinoma who received neoadjuvant pembrolizumab, carboplatin, and pemetrexed followed by robotic‐assiste...

Descripció completa

Dades bibliogràfiques

Autors principals:	Weijie Ma, Dana M. Ferrari‐Light, Liang Lu
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-04-01
Col·lecció:	Respirology Case Reports
Matèries:	AL amyloidosis immune checkpoint inhibitor lung adenocarcinoma neoadjuvant immunotherapy
Accés en línia:	https://doi.org/10.1002/rcr2.70586
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!